Significant Insider Selling Continues at Bluebird Bio (BLUE)

Thursday, October 19, 2017 10:15 PM ET

Significant Insider Selling Continues at Bluebird Bio (BLUE)

A SEC filing today indicated a substantial insider sale of Bluebird Bio shares as — Nick Leschly, Director and Officer — disposed of 10,823 shares in the company having a market value of approximately $1,569,840. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 1,000 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 11,823 shares and have averaged 5,912 shares per transaction over this time period.

The number of insider buy/sell trades at Bluebird Bio is above that of the 264 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 320 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by Bluebird Bio insiders is lower than its peers. Within the peer group there were 11,167,158 shares purchased and 12,498,262 shares sold with company insiders disposing of 4,160 shares on average over this time period.

To bring into focus significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated in data used to evaluate and write this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.